title: Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status.
abstract: OBJECTIVE
  Fibroblast growth factor 21 (FGF21) is an emerging metabolic regulator associated with glucose and lipid metabolism. However, previous studies of FGF21 have been largely confounded by obesity, and data are limited for advanced outcomes such as coronary artery disease (CAD) and ectopic fat accumulation. We investigated the associations between serum FGF21 concentrations and glucose/lipid metabolism, CAD, and pericardial fat deposition in subjects strictly matched for obesity parameters.
  
  
  METHODS
  We enrolled 189 patients who had undergone cardiac multidetector coronary computed tomography. We measured cardiometabolic parameters and serum FGF21 levels within body mass index (BMI)-matched groups. Correlations and linear regressions were analysed among serum FGF21 levels, pericardial fat volumes and cardiometabolic parameters. Serum FGF21 concentrations were compared in patients with and without diabetes, metabolic syndrome (MS) or CAD.
  
  
  RESULTS
  Serum FGF21 concentrations were significantly higher in BMI-matched patients with MS (107·2 ± 83·6 vs 82·1 ± 67·4 ng/l without MS, P < 0·05), but not among those with diabetes (84·3 ± 56·4 vs 96·3 ± 98·9 ng/l without diabetes, P = 0·300) or CAD (89·6 ± 65·8 vs 84·2 ± 83·1 ng/l without CAD, P = 0·633). Serum FGF21 concentrations correlated positively with triglycerides, low-density lipoprotein-cholesterol, insulin, HOMA-IR and pericardial fat volume. They showed an independent association with pericardial fat volume (β = 0·111 ± 0·053, P < 0·05).
  
  
  CONCLUSIONS
  Serum FGF21 concentrations were significantly associated with lipid profiles, insulin resistance, pericardial fat volume and MS, independently of obesity, but not with overt CAD or diabetes.
authors.affiliation: Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
authors.forename: Yenna
authors.initials: Y
authors.lastname: Lee
authors.forename: Soo
authors.initials: S
authors.lastname: Lim
authors.forename: Eun-Shil
authors.initials: ES
authors.lastname: Hong
authors.forename: Jung Hee
authors.initials: JH
authors.lastname: Kim
authors.forename: Min Kyung
authors.initials: MK
authors.lastname: Moon
authors.forename: Eun Ju
authors.initials: EJ
authors.lastname: Chun
authors.forename: Sang Il
authors.initials: SI
authors.lastname: Choi
authors.forename: Young-Bum
authors.initials: YB
authors.lastname: Kim
authors.forename: Young Joo
authors.initials: YJ
authors.lastname: Park
authors.forename: Kyong Soo
authors.initials: KS
authors.lastname: Park
authors.forename: Hak C
authors.initials: HC
authors.lastname: Jang
authors.forename: Sung Hee
authors.initials: SH
authors.lastname: Choi
mesh_terms: D000328:Adult; D003324:Coronary Artery Disease / Q000097:blood; D003331:Coronary Vessels / Q000473:pathology*; D005260:Female; D005346:Fibroblast Growth Factors / Q000097:blood*; D006801:Humans; D006946:Hyperinsulinism / Q000097:blood*; D015228:Hypertriglyceridemia / Q000097:blood*; D007333:Insulin Resistance / Q000502:physiology; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood*; D010496:Pericardium / Q000378:metabolism*
chemical_list: C414620:fibroblast growth factor 21; D005346:Fibroblast Growth Factors